Announcements
- Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
- Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
- Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
- Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights
- Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
- Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
- Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder
- Compass Pathways appoints Teri Loxam as Chief Financial Officer
- Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
- Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center
More ▼
Key statistics
On Friday, Compass Pathways PLC (CMPSN:MEX) closed at 171.68, 0.00% below its 52-week high of 171.68, set on Jan 26, 2024.
52-week range
Open | 171.68 |
---|---|
High | 171.68 |
Low | 171.68 |
Bid | 170.50 |
Offer | 171.68 |
Previous close | 171.68 |
Average volume | -- |
---|---|
Shares outstanding | 68.34m |
Free float | 3.66m |
P/E (TTM) | -- |
Market cap | 582.96m USD |
EPS (TTM) | -2.39 USD |
Data delayed at least 20 minutes, as of Jan 26 2024 11:30 GMT.
More ▼